Pre-clinical targeting of enzalutamide-resistant prostate cancer

Paul Toren(Hôtel-Dieu de Québec)

cIRcle (University of British Columbia)

January 1, 2017

10.14288/1.0340616

Cited by 0

Related Papers

Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)

|International Journal of Oncology|2014|158

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer

|PLoS ONE|2016|36

Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs

|Scientific Reports|2021|10